Conexeu Sciences, Inc. engages in the development of regenerative biomaterials needed in wound care, dentistry, and aesthetics. The company is headquartered in Reno, Nevada. The company went IPO on 2026-05-21. The firm is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The firm is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The firm operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies